Updated · Investors | Eli Lilly and Company · Apr 27
Eli Lilly acquires Ajax Therapeutics to obtain AJ1-11095 for blood cancer treatment
Updated
Updated · Investors | Eli Lilly and Company · Apr 27
Eli Lilly acquires Ajax Therapeutics to obtain AJ1-11095 for blood cancer treatment
13 articles · Updated · Investors | Eli Lilly and Company · Apr 27
The acquisition, valued at up to $2.3 billion, gives Lilly access to AJ1-11095, a Type II JAK2 inhibitor in Phase 1 trials for myelofibrosis and polycythemia vera.
AJ1-11095 aims to provide deeper and more durable efficacy than current JAK2 inhibitors, addressing resistance in patients with myeloproliferative neoplasms. The deal is subject to regulatory approval and customary closing conditions.
This move strengthens Lilly's blood-cancer portfolio and follows its recent acquisitions of Kelonia, Centessa, Orna, and Ventyx, reflecting its ongoing investment in innovative cancer therapies.
What makes this new drug a potential last hope for patients with resistant myelofibrosis?
How will this novel 'Type II' inhibitor disrupt the competitive market for treating rare blood cancers?
Can Lilly's new cancer therapy avoid the serious heart and cancer risks plaguing similar drugs?
Are mega-deals like Lilly's acquisition inflating a dangerous bubble in the biotech market?
Beyond weight-loss drugs, is Eli Lilly's shopping spree building the next pharmaceutical empire?